• Ranbaxy Laboratories Inc., of Princeton, N.J., a wholly owned subsidiary of Ranbaxy Laboratories Ltd., is planning to launch Absorica (isotretinoin) in the fourth quarter, now that the FDA has approved the drug for the treatment of severe recalcitrant nodular acne. Absorica is partnered with Mississauga, Ontario-based Cipher Pharmaceuticals Inc., which will receive royalties on net sales.